, Columnist
Incyte Is Smart to Date Around
It's leveraging a competitive market to get the most for its IO drug.
This article is for subscribers only.
When it comes to cancer drugs, monogamy is overrated.
Incyte Corp. recently announced an expanded collaboration with Merck & Co. on late-stage studies of combinations of immune-oncology (IO) drugs, which use a patient's immune system to fight cancer. Two days later, Incyte said it would also run similar late-stage trials with Merck's bitter IO rival Bristol-Myers Squibb Co. It already had earlier-stage trials ongoing with similar medicines from Roche Holding AG and AstraZeneca PLC.